Eyegate Stock Analysis

EYEG -  USA Stock  

USD 2.90  0.31  9.66%

The big decline in price over the last few months for Eyegate Pharma could raise concerns from shareholders as the firm it trading at a share price of 2.90 on very low momentum in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in June. However, diversifying your holdings with Eyegate Pharma or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.18. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Eyegate Pharma partners.
Continue to Investing Opportunities.

Search Stock Analysis 

 
Refresh
The Eyegate Pharma stock analysis report makes it easy to digest most publicly released information about Eyegate Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Eyegate Stock analysis module also helps to analyze the Eyegate Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Eyegate Stock Analysis Notes

About 56.0% of the company shares are held by institutions such as insurance companies. The book value of Eyegate Pharma was currently reported as 1.26. The company recorded a loss per share of 1.77. Eyegate Pharma had not issued any dividends in recent years. The entity had a split on the 30th of August 2019. EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts. Eyegate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To learn more about Eyegate Pharma call Stephen From at 781 788 8869 or check out http://www.eyegatepharma.com.

Eyegate Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Eyegate Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Eyegate Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Eyegate Pharma generates negative expected return over the last 90 days
Eyegate Pharma has high historical volatility and very poor performance
Eyegate Pharma was previously known as Eyegate Pharmaceuticals and was traded on NASDAQ Exchange under the symbol EYEGW.
The company reported the previous year's revenue of 12.06 K. Net Loss for the year was (8.72 M) with loss before overhead, payroll, taxes, and interest of (3.55 M).
Eyegate Pharma currently holds about 6.61 M in cash with (7.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93.
Eyegate Pharma has a frail financial position based on the latest SEC disclosures
Roughly 56.0% of the company shares are held by institutions such as insurance companies
Latest headline from bovnews.com: The Facts We Can Dig Up About EyeGate Pharmaceuticals Inc. s Stock - BOV News

Eyegate Pharma Upcoming and Recent Events

Earnings reports are used by Eyegate Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eyegate Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report8th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Eyegate Largest EPS Surprises

Earnings surprises can significantly impact Eyegate Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-08-06
2020-06-30-0.43-0.380.0511 
2021-03-25
2020-12-31-0.44-0.52-0.0818 
2019-08-08
2019-06-30-0.75-0.60.1520 
View All Earnings Estimates

Eyegate Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Eyegate Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Eyegate Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Eyegate Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
25th of June 2021
Submission of Matters to a Vote of Security Holders
View
27th of May 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
1st of April 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
5th of March 2021
Financial Statements and Exhibits
View
9th of February 2021
Unclassified Corporate Event
View
1st of February 2021
Financial Statements and Exhibits. Other Events. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
12th of January 2021
Unclassified Corporate Event
View
6th of January 2021
Financial Statements and Exhibits. Other Events. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View

Eyegate Pharma Thematic Classifications

In addition to having Eyegate Pharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Eyegate Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 23.42 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eyegate Pharma's market, we take the total number of its shares issued and multiply it by Eyegate Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Eyegate Profitablity

Eyegate Pharma's profitability indicators refer to fundamental financial ratios that showcase Eyegate Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Eyegate Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Eyegate Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Eyegate Pharma's profitability requires more research than a typical breakdown of Eyegate Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.68) (0.74) 
Return on Average Equity(1.08) (1.16) 
Return on Invested Capital 59.82  64.54 
Return on Sales(669.68) (687.31) 

Management Efficiency

The entity has return on total asset (ROA) of (32.04) % which means that it has lost $32.04 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (79.27) %, meaning that it created substantial loss on money invested by shareholders. Eyegate Pharma management efficiency ratios could be used to measure how well eyegate pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Invested Capital is expected to grow to 64.54, whereas Return on Average Assets are forecasted to decline to (0.74) . Eyegate Pharma Assets Non Current are projected to increase significantly based on the last few years of reporting. The past year's Assets Non Current were at 13.43 Million. The current year Tax Assets is expected to grow to about 19.7 K, whereas Goodwill and Intangible Assets are forecasted to decline to about 11.1 M.
Last ReportedProjected for 2021
Book Value per Share 1.53  1.65 
Enterprise Value over EBIT(2.00) (2.16) 
Enterprise Value over EBITDA(2.56) (2.76) 
Price to Book Value 3.26  3.52 
Tangible Assets Book Value per Share 0.42  0.43 
Enterprise Value20.2 M19.7 M
Tangible Asset Value1.9 MM

Technical Drivers

As of the 30th of July, Eyegate Pharma shows the mean deviation of 3.6, and Coefficient Of Variation of (973.88). Eyegate Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Eyegate Pharma, which can be compared to its rivals. Please confirm Eyegate Pharma treynor ratio, and the relationship between the standard deviation and downside variance to decide if Eyegate Pharma is priced favorably, providing market reflects its regular price of 2.9 per share. Please also check Eyegate Pharma total risk alpha, which is currently at (0.82) to verify the company can sustain itself at a future point.

Eyegate Pharma Price Movement Analysis

The output start index for this execution was four with a total number of output elements of fifty-seven. The Mid-point over period is an average of Eyegate Pharma highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Eyegate Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eyegate Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eyegate Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eyegate Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sarah Romano over three weeks ago via Macroaxis 
Payment of 180 shares by Sarah Romano of Eyegate Pharma subject to Rule 16b-3
Sarah Romano over a month ago via Macroaxis 
Payment of 180 shares by Sarah Romano of Eyegate Pharma subject to Rule 16b-3
Stephen From over two months ago via Macroaxis 
Payment of 898 shares by Stephen From of Eyegate Pharma subject to Rule 16b-3
Shapiro Aron over three months ago via Macroaxis 
Acquisition by Shapiro Aron of 4000 shares of Eyegate Pharma subject to Rule 16b-3
Sarah Romano over three months ago via Macroaxis 
Payment of 180 shares by Sarah Romano of Eyegate Pharma subject to Rule 16b-3
Sarah Romano over three months ago via Macroaxis 
Payment of 218 shares by Sarah Romano of Eyegate Pharma subject to Rule 16b-3
Obermayr Franz over three months ago via Macroaxis 
Acquisition by Obermayr Franz of 30000 shares of Eyegate Pharma subject to Rule 16b-3
Armistice Capital Llc over six months ago via Macroaxis 
Eyegate Pharmaceuticals exotic insider transaction detected
Sarah Romano over six months ago via Macroaxis 
Payment of 115 shares by Sarah Romano of Eyegate Pharmaceuticals subject to Rule 16b-3
Sarah Romano over six months ago via Macroaxis 
Payment of tradable shares by Sarah Romano of Eyegate Pharmaceuticals subject to Rule 16b-3
Sarah Romano over six months ago via Macroaxis 
Payment of tradable shares by Sarah Romano of Eyegate Pharmaceuticals subject to Rule 16b-3
Michael Manzo over six months ago via Macroaxis 
Payment of tradable shares by Michael Manzo of Eyegate Pharmaceuticals subject to Rule 16b-3

Eyegate Pharma Technical and Predictive Indicators

Eyegate Pharma Forecast Models

Eyegate Pharma time-series forecasting models is one of many Eyegate Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eyegate Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Eyegate Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Eyegate Pharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Eyegate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Eyegate Pharma. By using and applying Eyegate Stock analysis, traders can create a robust methodology for identifying Eyegate entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(2.91) (3.14) 
Gross Margin 0.90  0.89 
Profit Margin(3.04) (3.28) 
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts. Eyegate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Current Eyegate Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Eyegate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Eyegate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
14.5Strong Buy2Odds
Eyegate Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Eyegate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Eyegate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Eyegate Pharma, talking to its executives and customers, or listening to Eyegate conference calls.
Eyegate Analyst Advice Details

Eyegate Stock Analysis Indicators

Eyegate Pharma stock analysis indicators help investors evaluate how Eyegate Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Eyegate Pharma shares will generate the highest return on investment. By understating and applying Eyegate Pharma stock analysis, traders can identify Eyegate Pharma position entry and exit signals to maximize returns.
Quick Ratio4.74
Fifty Two Week Low3.2000
Shares Short Prior Month3.88k
Average Daily Volume Last 10 Day38.45k
Average Daily Volume In Three Month30.2k
Shares Percent Shares Out0.05%
Short Percent Of Float0.10%
Forward Price Earnings-2.20
Float Shares5.03M
Fifty Two Week High8.1800
Enterprise Value To Ebitda-3.08
Fifty Day Average4.0071
Two Hundred Day Average4.9943
Enterprise Value To Revenue2,137.83
Continue to Investing Opportunities. Note that the Eyegate Pharma information on this page should be used as a complementary analysis to other Eyegate Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Eyegate Stock analysis

When running Eyegate Pharma price analysis, check to measure Eyegate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyegate Pharma is operating at the current time. Most of Eyegate Pharma's value examination focuses on studying past and present price action to predict the probability of Eyegate Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Eyegate Pharma's price. Additionally, you may evaluate how the addition of Eyegate Pharma to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
The market value of Eyegate Pharma is measured differently than its book value, which is the value of Eyegate that is recorded on the company's balance sheet. Investors also form their own opinion of Eyegate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Eyegate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyegate Pharma's market value can be influenced by many factors that don't directly affect Eyegate Pharma underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyegate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Eyegate Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyegate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.